MetLife Investment Management’s Pulse Biosciences PLSE Stock Holding History

MetLife Investment Management’s Portfolio PLSE Stock Details PLSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$289K	Buy	10,438 +644	+7%	+$15.2K	﹤0.01%	2226
2026 Q1	$211K	Sell	9,794 -299	-3%	-$5.52K	﹤0.01%	2196
2025 Q4	$139K	Hold	10,093	–	–	﹤0.01%	2454
2025 Q3	$179K	Hold	10,093	–	–	﹤0.01%	2383
2025 Q2	$152K	Hold	10,093	–	–	﹤0.01%	2329
2025 Q1	$162K	Hold	10,093	–	–	﹤0.01%	2305
2024 Q4	$176K	Hold	10,093	–	–	﹤0.01%	2360
2024 Q3	$177K	Hold	10,093	–	–	﹤0.01%	2351
2024 Q2	$113K	Buy	10,093 +988	+11%	+$9.31K	﹤0.01%	2549
2024 Q1	$79.3K	Hold	9,105	–	–	﹤0.01%	2633
2023 Q4	$111K	Buy	+9,105	New	+$63K	﹤0.01%	2556
2021 Q4	–	Sell	-5,276	Closed	-$114K	–	2540
2021 Q3	$114K	Buy	+5,276	New	+$114K	﹤0.01%	2385
2021 Q2	–	Sell	-6,647	Closed	-$157K	–	2476
2021 Q1	$157K	Hold	6,647	–	–	﹤0.01%	2173
2020 Q4	$159K	Buy	+6,647	New	+$106K	﹤0.01%	2103

Other funds holding PLSE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

MetLife Investment Management's PLSE Position: Q2 2026 in Review

MetLife Investment Management increased its Pulse Biosciences (PLSE) stake by 6.6% in Q2 2026, buying an estimated $15.2K and bringing the position to 10,438 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #2226.

MetLife Investment Management first reported a position in PLSE in Q4 2020 and has held it in 14 quarters since. 106 funds tracked by Wall St. Rank hold PLSE as of Q2 2026.

MetLife Investment Management held 10,438 shares of Pulse Biosciences worth $289K as of Q2 2026.
MetLife Investment Management bought 644 Pulse Biosciences shares in Q2 2026, an estimated $15.2K.
Pulse Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2226 holding.
MetLife Investment Management first reported a position in Pulse Biosciences in Q4 2020 and has held it in 14 quarters since.
106 funds tracked by Wall St. Rank held Pulse Biosciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.